Gap

Researchers are evaluating a preventive, multidisciplinary primary care intervention designed for patients with cardio-neurovascular diseases. This intervention is centered around a therapeutic garden and aims to understand its acceptability to patients and those involved in the program. The study includes patients suffering from various vascular and cardiovascular conditions, including atrial fibrillation, heart failure (NYHA Class II), cardiomyopathies, ischemic stroke, and resistant hypertension. The intervention lasts six months and combines gardening activities, adapted physical exercise, and nutritional workshops as a comprehensive preventive approach. This multidisciplinary program is organized to provide therapeutic benefits through engagement in physical, social, and educational activities related to health and lifestyle. Participants are involved in the study from enrollment through the six-month treatment period, during which researchers monitor their acceptance of the intervention and identify factors that either help or hinder its implementation. The study collects data on how patients respond to and engage with the program, with a focus on understanding obstacles and facilitators to participation and adherence.

Numerous neurological disorders affecting the central and peripheral nervous system are linked to immune system activity. This research focuses on rare neuroimmune conditions such as Autoimmune Encephalitis (AE) and Paraneoplastic Neurological Syndromes (PNS). Improving diagnosis speed and accuracy for these disorders may help guide better treatment approaches in the future. Participants provide biological samples including blood and cerebrospinal fluid (CSF) for the study. Blood samples are collected once to obtain serum, buffy coat, plasma, and peripheral blood mononuclear cells (PBMC). If CSF is drawn for diagnosis, any leftover sample is also stored. Samples are collected and stored to support better diagnosis and research. During the study, participants contribute blood and possibly CSF samples which will be stored and analyzed over a long term, up to 10 years. Researchers will monitor these biological materials to better understand the disorders and develop improved diagnostic tools and treatments. The study involves consented patients with neurological disorders related to PNS or AE and may include antibody testing results.

Colorectal cancer mainly affects elderly patients, with over half of new cases in France occurring in those aged 70 or older. Adjuvant chemotherapy has shown benefits in disease-free and overall survival after stage III colon cancer surgery, but its use in elderly patients remains limited. This phase III randomized study explores whether adjuvant chemotherapy improves disease-free survival in elderly patients and which chemotherapy regimen is most effective, addressing concerns about benefits for both unfit and fit elderly patients. Participants will be divided into two groups based on a multidisciplinary evaluation including a geriatrician. One group will receive fluoropyrimidine-based chemotherapy (LV5FU2 or capecitabine), and the other will receive oxaliplatin-based chemotherapy (FOLFOX4 or XELOX). Some patients may be assigned to observation only. Treatments will begin within 12 weeks after surgery. The study also evaluates specific biological markers common in elderly tumors, such as mismatch repair deficiency. During the study, participants will undergo assessments including geriatric questionnaires and medical monitoring. Researchers will track disease-free survival over three years following the last patient's enrollment. Safety and treatment effects will be monitored, with exclusion of patients expected to live less than four years or those unable to comply with follow-up. The study aims to better understand chemotherapy benefits in an elderly population after colon cancer surgery.